Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder

Completed 52 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedSingle-groupOpen-label

Summary

To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR during 6 months of open-label treatment in elderly outpatients with major depressive disorder.

Timeline

Start: 2004-10
Primary completion: 2005-10
Completion: 2005-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DVS-233 SR	Unknown	—	—

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder

Summary

Timeline

Drugs

Indications